United Therapeutics Corporation (UTHR)

Market Cap	25.20B +32.1%
Revenue (ttm)	3.15B +2.5%
Net Income	1.31B +5.5%
EPS	27.95 +9.0%
Shares Out	42.89M
PE Ratio	21.02
Forward PE	20.84
Dividend	n/a
Ex-Dividend Date	n/a

Volume	637,856
Open	584.92
Previous Close	584.79
Day's Range	576.24 - 590.98
52-Week Range	409.07 - 609.35
Beta	0.49
Analysts	Buy
Price Target	661.29 (+12.56%)
Earnings Date	Nov 4, 2026

About UTHR

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of tre...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jun 17, 1999
• Employees: 1,400
• Stock Exchange: Nasdaq
• Ticker Symbol: UTHR
• Website: https://www.unither.com

Financial Performance

In 2025, United Therapeutics's revenue was $3.18 billion, an increase of 10.61% compared to the previous year's $2.88 billion. Earnings were $1.33 billion, an increase of 11.68%.

Analyst Summary

According to 15 analysts, the average rating for UTHR stock is "Buy." The 12-month stock price target is $661.29, which is an increase of 12.56% from the latest price.

Price Target

$661.29

(12.56% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 24, 2026

Data Sources Report a data error